Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether oral cephalexin is equivalent to intravenous cefazolin plus oral probenecid for the treatment of uncomplicated skin and soft tissue infections in patients that present to the emergency department.
| Condition | Intervention | Phase |
|---|---|---|
|
Cellulitis |
Drug: IV cefazolin plus oral probenecid and placebo cephalexin Drug: Oral cephalexin and saline IV plus probenecid placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Intravenous Cefazolin Plus Oral Probenecid vs. Oral Cephalexin for the Treatment of Cellulitis: a Randomized Controlled Trial |
- The proportion of patients failing therapy after 72 hours of antibiotic treatment with oral cephalexin or intravenous cefazolin plus oral probenecid. [ Time Frame: 72 hours ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 320 |
| Study Start Date: | May 2010 |
| Estimated Primary Completion Date: | August 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: IV cefazolin plus oral probenecid and placebo cephalexin |
Drug: IV cefazolin plus oral probenecid and placebo cephalexin
Intravenous cefazolin 2 g IV plus probenecid 1 g daily plus cephalexin placebo orally four times daily.
|
| Active Comparator: Oral cephalexin and saline IV plus probenecid placebo |
Drug: Oral cephalexin and saline IV plus probenecid placebo
Cephalexin 500 mg orally four times daily plus saline IV and oral probenecid placebo daily
|
Detailed Description:
Skin and soft tissue infections (SSTIs) are a common reason for presentation to an Emergency Department (ED) in Canada. Although many patients with mild SSTI are able to be managed at home with oral antibiotics, those with mild-moderate infections are often treated with parenteral antibiotics. Current practice patterns in Canadian EDs indicate this patient population is often treated with intravenous cefazolin once daily along with oral probenecid and return to the ED or other ambulatory setting for daily medication administration and assessment. This parenteral regimen has been found to result in success rates comparable to studies which have evaluated treatment success with oral antibiotics in this patient population (89-97%). Although successful outcome can be achieved with this approach, it is often inconvenient for the patient to return to the ED/ambulatory care unit daily and does contribute to overall ED/ambulatory care visit volumes and overall health care costs. Unfortunately, there has never been a study which has evaluated the relative efficacy and safety or oral antibiotics to the aforementioned parenteral approach in this patient population and thus there remains a significant knowledge gap which must be addressed before a change in current practice can be explored.
The objective of the study is to determine whether oral cephalexin is equivalent to intravenous cefazolin plus oral probenecid for the treatment of uncomplicated SSTIs in patients that present to the ED. This study will be a prospective, multi-centered, randomized controlled non-inferiority trial comparing cephalexin 500 mg orally four times to cefazolin 2 g IV plus probenecid 1 g orally, in patients presenting to the ED with presumed diagnosis of SSTI. The primary outcome will be to compare the proportion of patients failing therapy for their cellulitis after 72 hours of antibiotic treatment with oral cephalexin or IV cefazolin/oral probenecid 1 g daily. Secondary outcomes include the clinical cure rate at 7 days, percentage of patients requiring hospital admission, percentage of patients stepped down to oral antibiotics on or before day 7 of therapy, percentage of patients requiring an additional antibiotic prescription on day 7, and the frequency of adverse events.
Eligibility| Ages Eligible for Study: | 19 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients presenting to the emergency department with a presumed diagnosis of mild to moderate skin and soft tissue infection
- Deemed well enough to be treated as an outpatient
- 19 years of age or older
Exclusion Criteria:
- known allergy to study drugs
- known chronic kidney disease with a creatinine clearance <30 mL/min
- known previous methicillin-resistant staphylococcus aureus (MRSA) infection
- use of antibiotics for greater than 24 hours in the past 7 days
- wound/abscess requiring operative debridement or incision and drainage
- suspected necrotizing fasciitis, osteomyelitis or septic arthritis
- febrile neutropenia
- concomitant documented bacteremia
- Two or more signs of systemic sepsis
- new altered mental status
- infections at a site involving prosthetic materials
- animal or human bite wound infections
- post-operative wound infections
- known peripheral vascular disease
- superficial thrombophlebitis
- pregnant/breastfeeding
- obesity (BMI > 30 kg/m2)
Contacts and Locations| Canada, British Columbia | |
| Kelowna General Hospital | Recruiting |
| Kelowna, British Columbia, Canada, V1Y 1T2 | |
| Contact: Dawn Dalen, BSP, ACPR, PharmD (250) 862-4300 ext 7446 dawn.dalen@interiorhealth.ca | |
| Principal Investigator: Dawn Dalen, BSP, ACPR, PharmD | |
| Sub-Investigator: Denise Sprague, BSc. (Pharm), ACPR, PharmD | |
| Sub-Investigator: Jeffrey Eppler, MD, FRCP(C) | |
| Canada, Nova Scotia | |
| Queen Elizabeth II Health Sciences Centre | Recruiting |
| Halifax, Nova Scotia, Canada, B3H 1V7 | |
| Contact: Peter Zed, BSc, BSc (Pharm), ACPR, PharmD (902) 473-2967 peter.zed@cdha.nshealth.ca | |
| Principal Investigator: Peter Zed, BSc, BSc (Pharm), ACPR, PharmD | |
| Sub-Investigator: Samuel Campbell, MB BCh, CCFP(EM), Dip PEC (SA) | |
| Principal Investigator: | Dawn Dalen, PharmD | Interior Health, Canada |
| Principal Investigator: | Peter Zed, PharmD | Capital Health, Canada |
More Information
No publications provided
| Responsible Party: | Dawn Dalen and Peter Zed, Interior Health Authority and Capital Health Authority |
| ClinicalTrials.gov Identifier: | NCT01029782 History of Changes |
| Other Study ID Numbers: | KGHQEII-0001 |
| Study First Received: | December 9, 2009 |
| Last Updated: | June 14, 2011 |
| Health Authority: | Canada: Health Canada |
Keywords provided by Kelowna General Hospital:
|
Cellulitis Emergency Department Cefazolin Probenecid Cephalexin |
Additional relevant MeSH terms:
|
Cellulitis Skin Diseases, Infectious Infection Suppuration Connective Tissue Diseases Inflammation Pathologic Processes Cefazolin Cephalexin |
Probenecid Anti-Bacterial Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Uricosuric Agents Gout Suppressants Antirheumatic Agents Renal Agents |
ClinicalTrials.gov processed this record on May 23, 2013